IRF9 is also a key regulator according to PAH GRN, along with other 21 TFs, and regulates 189 PAH common overregulated DEGs, including LINC01089, which are co-expressed in lung cancer models and are related to cell development and differentiation, regulation of cellular component size, and cytoplasmic vesicle membrane and retromer complex binding (Table S1.3). This evidence concerns the gene IRF9 and lung carcinoma.